GlassScriptPhysician profile
Lydia B Speer
NPI 1073833364
$3,873.79
in general payments reported to CMS, 2019-2025
39 companies · $1,034 in 2025
The $1,034 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $142 · 2021: $16.39 · 2022: $438 · 2023: $532 · 2024: $1,097 · 2025: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,663.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $659.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $522.89 | 2022-2025 | Qulipta, Ubrelvy, Linzess |
| Astrazeneca Pharmaceuticals LP | $411.11 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $292.47 | 2019-2025 | |
| Abbott Laboratories | $206.99 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Insulet Corporation | $144.45 | 2024-2025 | Omnipod |
| Glaxosmithkline, LLC. | $130.32 | 2019-2025 | Shingrix, Arexvy |
| Amgen INC. | $126.82 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.77 | 2019-2024 | Jardiance |
| Antares Pharma, INC. | $108.63 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.72 | 2019-2024 | Trulance, Xifaxan |
| Lilly USA, LLC | $91.37 | 2019-2025 | Mounjaro, Jardiance |
| Astellas Pharma US INC | $83.15 | 2022-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $72.91 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.81 | 2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lydia Speer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.